Clinical Report: FDA Approves Cefepime-Zidebactam Injection
Overview
The FDA has approved cefepime and zidebactam for treating adults with complicated urinary tract infections (cUTIs), showing a clinical cure and microbiologic response rate of 89%.
Background
Complicated urinary tract infections (cUTIs) are a significant health concern, leading to over 600,000 hospitalizations annually in the US. The rise of multidrug-resistant bacterial infections poses a substantial burden on healthcare systems.
Data Highlights
| Parameter | Cefepime-Zidebactam | Meropenem |
|---|---|---|
| Composite clinical cure and microbiologic response rate | 89% | 68% |
Key Findings
- Cefepime and zidebactam approved for cUTIs and pyelonephritis caused by susceptible Gram-negative pathogens.
- Approval based on the phase 3 ENHANCE-1 trial involving 530 patients across multiple countries.
- Combination therapy achieved a significantly higher response rate compared to meropenem.
- Common adverse reactions include diarrhea, headache, hypertension, and hypokalemia.
- FDA granted Priority Review, Fast Track, and Qualified Infectious Disease Product designations for this treatment.
Clinical Implications
Awareness of potential adverse reactions and appropriate dosing adjustments for renal impairment is essential for safe administration.
Conclusion
The approval of cefepime and zidebactam marks a significant development in the fight against multidrug-resistant infections, offering hope for improved patient outcomes in complicated urinary tract infections.
Related Resources & Content
- Wockhardt, Press Release, 2026 -- FDA Approves Cefepime-Zidebactam Injection
- Open Forum Infectious Diseases, 2022 -- Efficacy of Aztreonam-Avibactam Against Carbapenem-Resistant Enterobacterales
- Infection, 2015 -- Emerging Antibiotics: Are We Still in the Transitional Phase of the Antibiotic Era?
- Infection, 2023 -- Prolonged Administration of Meropenem–Vaborbactam for Treating KPC-3-Producing Klebsiella pneumoniae
- IDSA, 2025 -- Guideline Update on Complicated Urinary Tract Infections
- Open Forum Infectious Diseases — Addressing Ceftaroline Resistance in MRSA Through the Use of Ceftaroline and Carbapenem Combination Therapy
- IDSA 2025 Guideline Update on Complicated Urinary Tract Infections
- Approval Label_220787Orig1s000lbl.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
